B. Braun Medical announces availability of FDA-approved Cefepime in DUPLEX System

 In an effort to meet industry demands for expanded Cephalosporin offerings delivered to patients through safe and accurate administration, B. Braun Medical Inc. (B. Braun) announced that FDA-approved 1g and 2g Cefepime for Injection USP and Dextrose Injection USP in B. Braun Medical Inc.'s DUPLEX® Drug Delivery System will be available for purchase beginning today.

"Infection control continues to be a critical challenge in today's continuum of care," said Rob Albert, Vice President of Pharmaceuticals and Drug Delivery Marketing for B. Braun Medical Inc. "The addition of 1g and 2g Cefepime for use in B. Braun's DUPLEX® System underscores our promise to provide healthcare professionals with solutions to improve the quality – and safety – of patient care delivery."

The availability of 1g and 2g Cefepime in the DUPLEX® System means faster, safer and accurate administration of Cefepime to patients as it can be stored ready-to-use in a container wherever and whenever it is needed.

To administer 1g or 2g Cefepime through DUPLEX®, healthcare workers simply fold and squeeze the container and shake it to mix the pharmaceuticals and diluent. A barcode that references the final admixture, lot number and expiration date helps reduce medication errors, automate patient charting, track inventory and facilitate reimbursement tracking.

The DUPLEX® Drug Delivery System is a ready-to-use, two-compartment, flexible, eco-friendly IV container that stores pre-measured pharmaceuticals and diluent doses. DUPLEX® is easy to stock as it can be stored at room temperature, with 18-month minimum dating, and fits in automated medication dispensing systems. Unit dose-based DUPLEX® helps healthcare facilities achieve Joint Commission and USP Chapter (797) compliance that improves the practice of healthcare professionals while advancing patient safety.

SOURCE B. Braun